Please click here for highlight broll footage, video and imagery of Vivid Sydney 2024 SYDNEY, June 17, 2024 /PRNewswire/ — The curtain will close tonight on Vivid Sydney 2024, after an incredible 23 days and nights of Light, Music, Food and Ideas. The lights will go out at 11pm across Vivid Sydney’s festival footprint which has […]
Category Archives: Pr Newswire
HONG KONG, June 17, 2024 /PRNewswire/ — Football fans are in for a treat as they gear up for UEFA EURO 2024™ with Toshiba TV’s top-performing Gaming TV Z670. As the OFFICIAL TV OF UEFA EURO 2024™, Toshiba TVs present immersive viewing of the football game by their AI-powered TV lineup. To celebrate the brilliant moments […]
HONG KONG, June 17, 2024 /PRNewswire/ — Building on the success of its inaugural edition during Marintec China 2017, Marintec Innovation Conference is back and better than ever! The conference has previously explored a number of fascinating themes, including ‘Cruise Shipbuilding, 2017’, ‘Smart Energy Efficiency Technologies for International Maritime, 2018’, ‘The Fourth Maritime Industrial Revolution, 2020’ […]
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world […]
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 Company will host a webcast conference today, June 16, 2024, at 9:00 a.m. […]
SEOUL, South Korea, June 16, 2024 /PRNewswire/ — In alignment with the global strategic development of Shandong Heavy Industry, with a focus on bolstering “doorstep” export business, from June 14th to 16th, Tan Xuguang led a delegation to South Korea to conduct a thorough market survey. The visit included in-depth assessments of the distribution channels for […]
The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy1 This Columvi combination could provide a much-needed off-the-shelf treatment option for people with transplant-ineligible R/R DLBCL Data were featured in […]
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with Mitapivat Compared to Placebo – – Agios to Webcast Virtual Investor Event on June 16, 2024 at 10 a.m. Eastern Time […]
SHANGHAI and NANJING, China and SAN JOSE, Calif., June 15, 2024 /PRNewswire/ — IASO biotechnology (“IASO Bio”), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented clinical data on the use of Equecabtagene Autoleucel (Eque-cel), the world’s first approved fully human CAR-T product, for the treatment of […]
SHANGHAI, June 15, 2024 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the initial results from the ongoing first-in-human study of CT071 have been presented at the 29th Annual Congress of the European Hematology Association […]

